Suppr超能文献

处方实践对尼日利亚西南部氯喹耐药性出现和传播的潜在贡献:青蒿素联合疗法的使用需谨慎。

Potential contribution of prescription practices to the emergence and spread of chloroquine resistance in south-west Nigeria: caution in the use of artemisinin combination therapy.

机构信息

Malaria Research Laboratories, Institute of Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.

出版信息

Malar J. 2009 Dec 30;8:313. doi: 10.1186/1475-2875-8-313.

Abstract

BACKGROUND

Prescription practices have been shown to influence the emergence of anti-malarial drug resistance. Thus efforts in this study were devoted to evaluating the prescribing practices prior to introduction of the artemisinin based combination therapy (ACT) in Nigeria and its potential contribution to emergence of chloroquine resistant malaria in south-west Nigeria, in order to forestall a similar situation with the ACT.

METHODS

A retrospective quantitative study was designed to examine case records of patients treated for malaria in either a government or a private hospital in Ibadan, south-west Nigeria, over a 20-year period, cutting across three phases of resistance to chloroquine in Nigeria: pre-resistance, emerging resistance and dissemination of resistance. Patient prescriptions were examined for use of anti-malarial drugs, sub-therapeutic doses of chloroquine, co-administration of anti-histamines with chloroquine. Descriptive statistics of frequency and percentage were used to describe trends in the parameters assessed using EPI-info.

RESULTS

Case record files of 2,529 patients were examined. Chloroquine was the main drug used in treatment of malaria throughout the periods studied, with frequency of prescription at both sites ranging from 91.4% to 98.3% during the pre-resistance years. It was administered as standard doses during the pre resistance years. Anti-histamines, especially promethazine, were routinely co-administered with chloroquine at this period too. However, the practice of prescribing sub-therapeutic doses of chloroquine at the private health care facility coincided with the latter phase of emerging resistance and phase of dissemination of resistance. Frequency of prescription of sub-therapeutic doses increased from 6.7% in 1983 (pre-resistance years) to 43.6% in 1997 (dissemination of resistance phase) at the private health care facility. Frequency of co-administration of anti-histamines with chloroquine also reduced during the period of dissemination of resistance.

CONCLUSION

The results from this study describe a lack of adherence to national treatment guidelines, especially in the private sector, and a relationship between prescription practices and dissemination of drug resistant falciparum malaria. As Nigeria adopts the use of ACT, there is an urgent need to improve malaria treatment practices in Nigeria in order to prolong the clinical shelf-life of the combination.

摘要

背景

处方实践已被证明会影响抗疟药物耐药性的出现。因此,本研究致力于评估在尼日利亚引入青蒿素为基础的联合疗法(ACT)之前的处方实践情况,以及其对抗疟药物耐药性疟疾在尼日利亚西南部出现的潜在贡献,以便避免 ACT 出现类似情况。

方法

设计了一项回顾性定量研究,以检查在尼日利亚西南部伊巴丹的一家政府医院或一家私人医院接受疟疾治疗的患者的病历记录,跨越了尼日利亚对氯喹耐药性的三个阶段:耐药前、耐药出现和耐药传播。检查了患者的处方,以评估抗疟药物的使用情况、氯喹的亚治疗剂量、氯喹与抗组胺药物的联合使用情况。使用 EPI-info 描述频率和百分比的描述性统计数据来描述所评估参数的趋势。

结果

检查了 2529 名患者的病历档案。氯喹一直是治疗疟疾的主要药物,在研究期间,两个地点的处方频率均在耐药前年份高达 91.4%至 98.3%。在耐药前年份,氯喹按标准剂量使用。在此期间,抗组胺药物,特别是异丙嗪,也与氯喹常规联合使用。然而,在私人医疗机构开具氯喹亚治疗剂量的做法与耐药出现的后期阶段和耐药传播阶段同时发生。在私人医疗机构开具亚治疗剂量的处方频率从 1983 年(耐药前年份)的 6.7%增加到 1997 年(耐药传播阶段)的 43.6%。在耐药传播阶段,与氯喹联合使用抗组胺药物的频率也有所降低。

结论

本研究结果描述了缺乏遵守国家治疗指南的情况,特别是在私营部门,以及处方实践与耐药恶性疟原虫疟疾传播之间的关系。随着尼日利亚采用 ACT,尼日利亚迫切需要改善疟疾治疗实践,以延长该联合疗法的临床保质期。

相似文献

引用本文的文献

本文引用的文献

8
Viewpoint: management of malaria--working with the private sector.观点:疟疾管理——与私营部门合作
Trop Med Int Health. 1999 May;4(5):402-6. doi: 10.1046/j.1365-3156.1999.00411.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验